



MEMORANDUM TO: FILE

FROM: Deborah A. Piskura, Senior Health Physicist 

THRU: Aaron T. McCraw, Chief, Materials Inspection Branch 

SUBJECT: SPECIAL INSPECTION CONDUCTED AT QHG OF INDIANA, INC. (LICENSE NO. 13-01535-01, DOCKET NO. 030-01594)

This special inspection was conducted on June 13, 2016, at the request of Region III management to review the licensee's use of Section 35.400 materials. This information served as a supplement to Inspection Report No. 03001594/2016001(DNMS)

This licensee was authorized for iodine-125, palladium-103, and cesium-131 sources permitted by Section 35.400 for permanent prostate implants. The licensee retained the services of an independent radiation oncology firm to perform the treatment planning and dose calculations. The patient records were maintained at the adjacent cancer center on the QHG of Indiana campus; the radiation oncology firm also operated the adjacent cancer center. According to the staff at the cancer center, the last prostate implant occurred in October 2012. The inspector reviewed the implant log book and the treatment records for this October 2012 case. The inspector interviewed select staff in the licensee's nuclear medicine department and observed the storage area for the unused/extra seeds from previous implants. The licensee staff confirmed that the last case was implanted in 2012. The licensee maintained its unused/extra seeds in secured storage and intended to transfer these seeds for disposal. The staff could not anticipate any future use of Section 35.400 materials.

No violations of NRC requirements were identified.